We are pleased to announce that ASLAN Pharmaceuticals has secured US$34 million in a Series C financing. The financing was led by Accuron Technologies Limited, a wholly-owned subsidiary of Temasek Holdings. Accuron is a global technology and engineering group with a leading global medical device and diagnostics business division – Accuron MedTech. Other new investors included Tianda Pharmaceuticals Limited and Haitong International. Existing investors Morningside, Bioveda, Cenova and Sagamore Bioventures also participated in the round.

For more details of the funding, please refer to the English or Chinese press release.